Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

A New Prognostic Scoring Model in Myelodysplastic Neoplasms

Baoqing Yang, Jie Zhou, Hao Wu, Shaoguang Li, Aibin Liang, Jianfei Fu

Blood (2024) 144 (Supplement 1): 6702.

https://doi.org/10.1182/blood-2024-202368

Published: 2024

Journal Articles

A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Blood (2024) 144 (Supplement 1): 989.

https://doi.org/10.1182/blood-2024-194581

Published: 2024

Journal Articles

A Prospective Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with Relapsed/Refractory Multiple Myeloma Including Those with Extramedullary Disease

Hua Jiang, Lu Li, Kaili Chen, Chunchen Yang, Ruixue Ma, Liangyu Xie, Can He, Fang Feng, Hao Wu, Xiaomei Chen, Dan Li, Xianghai Cai, Jin Zhao, Tao Guan, Li Ma, Min Bai, Guoxiang Wu, Liping Su, Weijun Fu

Blood (2024) 144 (Supplement 1): 923.

https://doi.org/10.1182/blood-2024-201160

Published: 2024

Journal Articles

Brigatinib Monotherapy in Children with R/R ALK+ ALCL, IMT, or Other Solid Tumors: Updated Results from the Brigaped (ITCC-098) Phase 1 Dose-Escalation Study

Blood (2024) 144 (Supplement 1): 3108.

https://doi.org/10.1182/blood-2024-200077

Published: 2024

Journal Articles

ITGB3 Promotes the Progression of JAK2V617F-Positive Myeloproliferative Neoplams By Regulating Calreticulin to Inhibit Cellular Autophagy

Jie Zhou, Wenjun Zhang, Baoqing Yang, Hao Wu, Bing Li, Shaoguang Li, Aibin Liang, Jianfei Fu

Blood (2023) 142 (Supplement 1): 2748.

https://doi.org/10.1182/blood-2023-181816

Published: 2023

Journal Articles

Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Primary Analysis of a Phase Ib/II Study

Blood (2023) 142 (Supplement 1): 613.

https://doi.org/10.1182/blood-2023-174209

Published: 2023

Journal Articles

Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma

Ting Du, Yan Song, Arghya Ray, Xueping Wan, Yao Yao, Mehmet K. Samur, Chen Shen, Johany Penailillo, Tomasz Sewastianik, Yu-Tzu Tai, Mariateresa Fulciniti, Nikhil C. Munshi, Hao Wu, Ruben D. Carrasco, Dharminder Chauhan, Kenneth C. Anderson

Blood (2023) 141 (21): 2599–2614.

https://doi.org/10.1182/blood.2022017897

Published: 2023

Includes: Supplemental data

Journal Articles

Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and ≥65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and ≥1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study

Adam J. Olszewski, L. Elizabeth Budde, Julio Chavez, Nilanjan Ghosh, Manali Kamdar, Izidore S. Lossos, Catherine Diefenbach, Waleed Sabry, Kathleen Dorritie, Ling-Yuh Huw, Song Pham, Ting Jia, Hao Wu, Iris To, Michael C. Wei, Sarit Assouline

Blood (2022) 140 (Supplement 1): 3757–3759.

https://doi.org/10.1182/blood-2022-159594

Published: 2022

Journal Articles

SUNMO: A Phase III Trial Evaluating the Efficacy and Safety of Mosunetuzumab in Combination with Polatuzumab Vedotin Versus Rituximab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Jason Westin, Adam J. Olszewski, Laura Maria Fogliatto, Won-Seog Kim, Ho-Jin Shin, Hao Wu, Shen Yin, Song Pham, Elicia Penuel, Jing Jing, Michael C. Wei, Elizabeth L. Budde

Blood (2022) 140 (Supplement 1): 3771–3772.

https://doi.org/10.1182/blood-2022-157710

Published: 2022

Journal Articles

Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell–like blasts in KMT2A -rearranged leukemia

Blood (2022) 139 (14): 2198–2211.

https://doi.org/10.1182/blood.2021013442

Published: 2022

Includes: Supplemental data

Journal Articles

Single-Cell Multiomics Reveals Increased Plasticity, Resistant Populations and Stem-Cell-like Blasts in KMT2A-Rearranged Leukemia

Blood (2021) 138 (Supplement 1): 2203.

https://doi.org/10.1182/blood-2021-146102

Published: 2021

Journal Articles

BCL10 Gain-of-Function Mutations Aberrantly Induce Canonical and Non-Canonical NF-Kb Activation and Resistance to Ibrutinib in ABC-DLBCL

Min Xia, Liron David, PhD, Matthew Teater, PhD, Ozlem Onder, PhD MSc, Kojo S. J. Elenitoba-Johnson, MD, Lorena Fontan, PhD, Hao Wu, PhD, Ari Melnick, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-141363

Published: 2020

Journal Articles

Chemically Induced Degradation of MALT1 to Treat B-Cell Lymphomas

Lorena Fontan, PhD, John Hatcher, PhD, David Scott, Qi Qiao, Ilkay Us, Guangyan Du, Matthew Durant, Jimmy Wilson, Hao Wu, PhD, Nathanael Gray, Ari Melnick, MD

Blood (2019) 134 (Supplement_1): 2073.

https://doi.org/10.1182/blood-2019-130666

Published: 2019

Journal Articles

CRISPR/dCas9 (D10A) -Mediated Hb CS Gene Editing and Identification of Genetically Modified Fibroblasts

Lian Yu, Wei Hao Wu, WANG Shunqing, Ken H. Young, Funeng Jiang, PhD

Blood (2019) 134 (Supplement_1): 5754.

https://doi.org/10.1182/blood-2019-129931

Published: 2019

Journal Articles

Low-Dose Interleukin-2 Restores Human Regulatory T Cell Function, in Vitro , As a Potential in the Handle of Graft Versus Host Disease (GvHD)

Tzeon-Jye Chiou, MD, Hsiu-Hsia Lin, PhD, Wei-Hao Wu, BS, Jhih-Yun Jian, MS, Sin-Tak Chu, PhD, Woan-Fang Tzeng, PhD

Blood (2017) 130 (Supplement 1): 5450.

https://doi.org/10.1182/blood.V130.Suppl_1.5450.5450

Published: 2017

Journal Articles

Calvariae-Resident Osteomacs That Are Phenotypically and Functionally Distinct from Marrow-Derived Macrophages Interact with Megakaryocytes to Regulate Hematopoietic Stem Cell Function

Safa F Mohamad, Linlin Xu, Himes R Evan, Hao Wu, Marta Alvarez, Paul Childress, Korbin Davis, Melissa Kacena, Edward F. Srour, PhD

Blood (2016) 128 (22): 28.

https://doi.org/10.1182/blood.V128.22.28.28

Published: 2016

Journal Articles

Expansion and Reactivation of Human Naïve T-Cells Transition into CD4+CD25+FoxP3+CD127-Regulatory T Cells, In Vitro , for the Potential Use of Graft-Versus-Host Disease Prevention

Tzeon-Jye Chiou, MD, Tien-Hua Chu, PhD, Wei-Hao Wu, MS, Sin-Tak Chu, PhD, Woan-Fang Tzeng, PhD

Blood (2016) 128 (22): 5729.

https://doi.org/10.1182/blood.V128.22.5729.5729

Published: 2016

Journal Articles

CD166 Identifies Multiple Myeloma Cells That Preferentially Home to the Bone Marrow Microenvironment and Promote Disease Progression and Bone Lytic Disease

Linlin Xu, Christophe Machal, Hao Wu, Colin D Crean, Bradley Poteat, Angelo A. Cardoso, Helmut Hanenberg, Khalid Mohammad, Attaya Suvannasankha, Edward F Srour

Blood (2014) 124 (21): 174.

https://doi.org/10.1182/blood.V124.21.174.174

Published: 2014

Journal Articles

A Novel Mutation In Bruton Tyrosine Kinase Confers Acquired Resistance To Ibrutinib (PCI-32765) In CLL

Richard R. Furman, MD, Shuhua Cheng, PhD, Pin Lu, MD, PhD, Menu Setty, Alexandar Perez, Ailin Guo, MD, PhD, Joelle Racchumi, BS, Jiao Ma, PhD, Morton Coleman, MD, Kabaleeswaran Venkataraman, PhD, Guozhou Xu, PhD, Wei Chen, PhD, Hao Wu, PhD, Betty Y. Chang, PhD, Christina Leslie, PhD, Y. Lynn Wang, MD, PhD

Blood (2013) 122 (21): 4914.

https://doi.org/10.1182/blood.V122.21.4914.4914

Published: 2013

Journal Articles

Role Of CD166 In Multiple Myeloma Cell Homing To The Bone Marrow Microenvironment and Disease Progression

Linlin Xu, Christophe Machal, Hao Wu, Bradley Poteat, Colin D. Crean, Angelo A. Cardoso, MD, PhD, John M Chirgwin, PhD, Helmut Hanenberg, MD, Khalid S. Mohammad, M.D. Ph.D., Attaya Suvannasankha, MD, Edward F Srour, PhD

Blood (2013) 122 (21): 3102.

https://doi.org/10.1182/blood.V122.21.3102.3102

Published: 2013

NARROW

A New Prognostic Scoring Model in Myelodysplastic Neoplasms

A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

A Prospective Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with Relapsed/Refractory Multiple Myeloma Including Those with Extramedullary Disease

Brigatinib Monotherapy in Children with R/R ALK+ ALCL, IMT, or Other Solid Tumors: Updated Results from the Brigaped (ITCC-098) Phase 1 Dose-Escalation Study

ITGB3 Promotes the Progression of JAK2V617F-Positive Myeloproliferative Neoplams By Regulating Calreticulin to Inhibit Cellular Autophagy

Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Primary Analysis of a Phase Ib/II Study

Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma

Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and ≥65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and ≥1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study

SUNMO: A Phase III Trial Evaluating the Efficacy and Safety of Mosunetuzumab in Combination with Polatuzumab Vedotin Versus Rituximab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell–like blasts in KMT2A -rearranged leukemia

Single-Cell Multiomics Reveals Increased Plasticity, Resistant Populations and Stem-Cell-like Blasts in KMT2A-Rearranged Leukemia

BCL10 Gain-of-Function Mutations Aberrantly Induce Canonical and Non-Canonical NF-Kb Activation and Resistance to Ibrutinib in ABC-DLBCL

Chemically Induced Degradation of MALT1 to Treat B-Cell Lymphomas

CRISPR/dCas9 (D10A) -Mediated Hb CS Gene Editing and Identification of Genetically Modified Fibroblasts

Low-Dose Interleukin-2 Restores Human Regulatory T Cell Function, in Vitro , As a Potential in the Handle of Graft Versus Host Disease (GvHD)

Calvariae-Resident Osteomacs That Are Phenotypically and Functionally Distinct from Marrow-Derived Macrophages Interact with Megakaryocytes to Regulate Hematopoietic Stem Cell Function

Expansion and Reactivation of Human Naïve T-Cells Transition into CD4+CD25+FoxP3+CD127-Regulatory T Cells, In Vitro , for the Potential Use of Graft-Versus-Host Disease Prevention

CD166 Identifies Multiple Myeloma Cells That Preferentially Home to the Bone Marrow Microenvironment and Promote Disease Progression and Bone Lytic Disease

A Novel Mutation In Bruton Tyrosine Kinase Confers Acquired Resistance To Ibrutinib (PCI-32765) In CLL

Role Of CD166 In Multiple Myeloma Cell Homing To The Bone Marrow Microenvironment and Disease Progression

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only